Print Page

藥 物 回 收

 
Canada: Leo Pharma Canada Inc. Product Recall (English only)
 
Health Canada announces that Leo Pharma Canada Inc. is recalling the following products from wholesalers, retailers and pharmacy:
- Picato (ingenol mebutate) 0.015% Topical Gel (lot number: A92594A, A98939A and C09552A)
- Picato (ingenol Mebutate) 0.05% Topical Gel (lot number: A95625A and C03414A)

Following the review of safety and efficacy information, it was concluded that there may be a link between Picato and an increased risk of skin cancer.

Please refer to the following website in Health Canada for details: http://www.healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/../74261r-eng.php

In Hong Kong, the above products are not registered pharmaceutical products. Related news was previously issued by various overseas drug regulatory authorities, and was posted on the Drug Office website since 19 Oct 2019, with the latest update posted on 28 Oct 2020.

Ends/Wednesday, Nov 4, 2020
Issued at HKT 15:00
 
Related Information:
Canada: PICATO (ingenol mebutate gel, 0.015% and 0.05%): Product withdrawal in C... 上載於 2020-10-28
Canada: Summary Safety Review: Picato (ingenol mebutate): Assessing the Potentia... 上載於 2020-07-03
European Union: Risks of Picato for actinic keratosis outweigh benefits (English... 上載於 2020-05-02
European Union: EMA review of Picato concludes medicine’s risks outweigh its ben... 上載於 2020-04-18
The United Kingdom: Ingenol mebutate gel (Picato▼): suspension of the licence du... 上載於 2020-02-13
The United Kingdom: Class 2 Medicines Recall: LEO Laboratories Ltd, Picato 150 m... 上載於 2020-01-29
European Union: EMA suspends Picato as a precaution while review of skin cancer ... 上載於 2020-01-18
The United Kingdom: Ingenol mebutate gel (Picato): increased incidence of skin t... 上載於 2019-10-19
 
back